NASDAQ · Medical - Pharmaceuticals

DMRA (DMRA) Stock

$29.14 +2.86% NASDAQ: DMRA Healthcare

Valuation

MetricValue
Price$29.14
Market Cap$1.79B
P/E Ratio-9.46
P/B Ratio5.80
P/S Ratio0.00
EPS (TTM)$-2.44
52-Week High$38.33
52-Week Low$2.45
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1.64%
ROA-16.46%
ROCE-87.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio12.98

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-52.0M$-61.0M$-36.0M$-17.0M$-211.0M
Net Profit$-52.0M$-62.0M$-38.0M$-21.0M$-210.0M
EPS$-51.22$-60.63$-36.08$-18.53$-158.13
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$122.0M$73.0M$38.0M$17.0M$261.0M
Total Liabilities$5.0M$11.0M$6.0M$3.0M$20.0M
Cash$63.0M$33.0M$21.0M$14.0M$258.0M
Borrowings$1.0M$1.0M$0$1.0M$0

Latest News

Damora Therapeutics Completes Redomestication to Cayman Islands MT Newswires · Jul 17, 2026 Damora Announces Redomestication from Delaware to Cayman Islands GlobeNewswire · Jul 17, 2026 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 1, 2026 HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target MT Newswires · Jun 11, 2026 TD Cowen Initiates Damora Therapeutics at Buy MT Newswires · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-52.0M$-43.0M$-37.0M$-19.0M$-7.0M
Investing Cash Flow$-48.0M$12.0M$22.0M$12.0M$-17.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-101.0M$-30.0M$-11.0M$-7.0M$243.0M
Free Cash Flow$-53.0M$-43.0M$-37.0M$-19.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-42.45
FCF Yield0.04%
Quick Ratio12.98
Interest Coverage—
Return 1Y651.91%
Return 3Y-51.43%
Return 5Y-74.06%

Ownership

Insiders Held7.62%
Institutions Held94.05%
Institutions Float Held101.81%
Institutional HolderSharesReport Date
FMR, LLC9,045,4812026-03-31
Fairmount Funds Management LLC8,713,0002026-03-31
Avoro Capital Advisors LLC3,783,0002026-03-31
Venrock Adviser, LLC3,603,5952026-03-31
FCPM III Services B.V.2,441,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About DMRA

DMRA is led by CEO Jennifer A. Jarrett, employs 7 people, headquartered in US, publicly traded since 2026.

DMRA stock trades at $29.14 with a market capitalization of $1.79B. The stock is valued at a price-to-earnings (P/E) ratio of -9.46, price-to-book of 5.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.45 and $38.33, and currently trades 24.0% below its 52-week high.

On profitability, DMRA generates a return on equity (ROE) of -1.64%, return on capital employed of -87.55%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides